CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
We are very excited to launch our new website! Please take a few moments to click around and explore...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...